To include your compound in the COVID-19 Resource Center, submit it here.

ImClone resubmits Erbitux BLA

As planned, IMCL submitted a BLA to the FDA for Erbitux cetuximab in combination

Read the full 142 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE